By physician referral or invitation only

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients with Sickle Cell Disease

Study the effectiveness and safety of Epeleuton

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Samuel Wilson
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Rare Diseases

IRB Number

23-3195

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

My UNC Chart
Find a Doctor
Accessibility
Privacy Policy
For Researchers

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.